Plaquenil (hydroxychloroquine) is not a blood thinner. It belongs to a class of drugs called 4-aminoquinoline compounds and is FDA-approved for treating lupus, rheumatoid arthritis, and malaria. However, it does have measurable effects on blood clotting that make this a more nuanced question than a simple yes or no.
What Plaquenil Actually Does
Blood thinners fall into two categories: anticoagulants (like warfarin and heparin) that interfere with clotting factors in your blood, and antiplatelets (like aspirin) that prevent blood cells called platelets from clumping together. Plaquenil is neither of these. It’s classified as a disease-modifying antirheumatic drug (DMARD), meaning its primary job is calming an overactive immune system to reduce inflammation and joint damage in autoimmune conditions.
That said, Plaquenil does influence how platelets behave. Research shows it can slow platelet buildup on blood vessel walls, reduce platelet activation, and interfere with several of the chemical pathways platelets use to form clots. These include blocking a key surface receptor that platelets need to stick to fibrinogen (a clotting protein), inhibiting the release of signaling molecules from platelet storage granules, and stabilizing platelet membranes so they’re less reactive. In animal models, hydroxychloroquine inhibited clot formation in carotid arteries and reduced the accumulation of a clotting protein called von Willebrand factor within those clots.
So while Plaquenil isn’t prescribed as a blood thinner, it has real antiplatelet activity that can matter clinically.
Why This Matters for Lupus and Clotting Disorders
People with lupus and antiphospholipid syndrome (APS) face a significantly higher risk of dangerous blood clots. This is one reason doctors consider Plaquenil so valuable in these conditions: beyond controlling inflammation, it appears to offer protection against clotting events.
In a study published in the Journal of Thrombosis and Haemostasis, researchers followed 40 patients with primary antiphospholipid syndrome who were already on standard anticoagulant therapy. Half had hydroxychloroquine (400 mg daily) added to their regimen, while the other half continued with anticoagulants alone. The group without hydroxychloroquine experienced six recurrent blood clots (three in the thigh veins, three in the lower leg veins) over the follow-up period. The difference between the two groups was statistically significant, with a hazard ratio of 2.4, meaning patients not taking hydroxychloroquine were roughly 2.4 times more likely to develop a new clot.
Hydroxychloroquine also appears to directly counteract the antibodies that drive clotting in antiphospholipid syndrome. It reduces the binding of these problematic antibodies to cell surfaces and helps restore a protective protein layer on cells that normally prevents unwanted clotting. In lab testing, this translated to coagulation times returning closer to normal levels.
Interactions With Actual Blood Thinners
Because Plaquenil has its own antiplatelet properties, combining it with blood thinners or antiplatelet drugs can increase bleeding risk. When hydroxychloroquine is added to aspirin, the combined inhibition of platelet clumping is significantly greater than aspirin alone. If you take both, your doctor may want to monitor you more closely.
The blood thinner clopidogrel (Plavix) presents a different concern. Clopidogrel can interfere with the liver enzymes that break down hydroxychloroquine, potentially raising Plaquenil levels in your blood. Higher concentrations of hydroxychloroquine increase the risk of a heart rhythm problem called QT prolongation. The blood thinner dabigatran also requires close monitoring when taken alongside Plaquenil.
Before Surgery
Unlike actual blood thinners, which typically need to be stopped days or weeks before a procedure, Plaquenil is generally continued through surgery. The American College of Rheumatology’s 2022 perioperative management guideline addresses this, and the standard practice for DMARDs like hydroxychloroquine is to keep taking them around the time of surgery. This is another practical distinction between Plaquenil and true blood thinners: its effects on clotting are modest enough that surgeons don’t usually consider it a bleeding risk worth interrupting treatment for.
The Bottom Line on Clotting Effects
Plaquenil sits in an unusual middle ground. It’s not prescribed to thin your blood, and it won’t show up on a list of anticoagulants or antiplatelets. But it genuinely reduces platelet reactivity and clot formation through multiple biological pathways. For people with lupus or antiphospholipid syndrome, this is actually a bonus, offering some clot protection on top of its anti-inflammatory effects. For everyone taking it, the antiplatelet activity is mild enough that it rarely causes bleeding problems on its own, but strong enough that it matters when combined with drugs that do thin the blood.